Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; sodium starch glycollate; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of postmenopausal women with hormone receptor positive breast cancer (see "clinical trials"). the safety and efficacy of neoadjuvant use has not been established. letrozole is not indicated in hormone receptor negative disease.

United States - English - NLM (National Library of Medicine)

chartwell rx, llc - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole tablets, usp are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. letrozole tablets, usp are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole for a median of 60 months [ see clinical studies ( 14.2 , 14.3 ) ]. letrozole tablets, usp are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.letrozole tablets, usp are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression fol

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - letrozole - film coated tablet - 2.5 milligram - letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - letrozole - film coated tablet - 2.5 milligram - letrozole

Malta - English - Medicines Authority

accord healthcare limited - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; maize starch; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; triacetin; iron oxide yellow; iron oxide red; quinoline yellow aluminium lake; polydextrose - for the treatment of postmenopausal women with hormone receptor positive breast cancer. the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy